IGX — Intelgenx Technologies Share News
0.000.00%
Last trade - 00:00- CA$41.92m
- CA$62.83m
- $1.04m
Brief: Intelgenx Facility Undergoes U.S. FDA Pre-Approval Inspection Related To Rizaport NDA
Brief: Intelgenx Partners With Gensco Pharma To Market RIZAPORT In The U.S.
Brief: Intelgenx Announces FDA Acceptance New Drug Application Resubmission For Rizaport
Brief: Intelgenx Reports Third Quarter 2018 Financial Results
Brief: Intelgenx Announces Pricing Of $12 Mln Equity Offering
Brief: Intelgenx Technologies Corp Files For Mixed Shelf Of Up To $100 mln
Brief: IntelGenx Says Study Results Demonstrated Rizaort Is Bioequivalent To U.S. Reference, Maxalt-MTL
Brief: Intelgenx Technologies Corp QTRLY Loss Per Share $0.04
Brief: Intelgenx Announces Settlement Of Suboxone Patent Litigation
Brief: IntelgenX Qtrly Loss Per Share $0.03
Brief: Intelgenx Announces Proposed Private Placement
Brief: Intelgenx Q4 Revenue $1.5 Mln
Brief: Intelgenx Announces Proposed Private Placement
Brief: Intelgenx Announces Proposed Acquisition Of Laboval
Brief: IntelGenx Clarifies Recent Preliminary 2018 Proxy Statement Filing
Brief: Intelgenx Says Its Site Obtained Amended Drug Establishment License For Manufacturing Activities
Brief: IntelGenx Receives Health Canada Clearance To Begin Phase 2a Study With Montelukast Versafilm
Brief: Intelgenx to regain exclusive worldwide rights to develop and commercialize rizaport(r)
Brief: IntelGenx submits Montelukast VersaFilm(tm) clinical trial application with Health Canada